ETHRIL 250 Drug Patent Profile
✉ Email this page to a colleague
When do Ethril 250 patents expire, and when can generic versions of Ethril 250 launch?
Ethril 250 is a drug marketed by Bristol Myers Squibb and is included in one NDA.
The generic ingredient in ETHRIL 250 is erythromycin stearate. There are one hundred and three drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the erythromycin stearate profile page.
Summary for ETHRIL 250
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 26 |
Patent Applications: | 1 |
Formulation / Manufacturing: | see details |
DailyMed Link: | ETHRIL 250 at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for ETHRIL 250
US Patents and Regulatory Information for ETHRIL 250
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bristol Myers Squibb | ETHRIL 250 | erythromycin stearate | TABLET;ORAL | 061605-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |